Bosh sahifaPHIO • NASDAQ
add
Phio Pharmaceuticals Corp
Yopilish kursi
2,21 $
Kunlik diapazon
2,15 $ - 2,26 $
Yillik diapazon
0,97 $ - 9,79 $
Bozor kapitalizatsiyasi
10,51 mln USD
Oʻrtacha hajm
545,58 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 1,86 mln | -16,35% |
Sof foyda | -1,77 mln | 17,87% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | — | — |
EBITDA | -1,87 mln | 15,24% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 13,28 mln | 105,07% |
Jami aktivlari | 13,44 mln | 96,12% |
Jami passivlari | 1,27 mln | 1,68% |
Umumiy kapital | 12,17 mln | — |
Tarqatilgan aksiyalar | 4,80 mln | — |
Narxi/balansdagi bahosi | 0,87 | — |
Aktivlardan daromad | -48,81% | — |
Kapitaldan daromad | -55,41% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -1,77 mln | 17,87% |
Operatsiyalardan naqd pul | -1,28 mln | 36,60% |
Sarmoyadan naqd pul | -2,00 ming | — |
Moliyadan naqd pul | 9,17 mln | 229 425,00% |
Naqd pulning sof oʻzgarishi | 7,90 mln | 491,86% |
Boʻsh pul | -678,00 ming | 43,76% |
Haqida
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Tashkil etilgan
2011
Sayt
Xodimlar soni
5
